Gilde Healthcare is a healthcare investor that does lower mid-market buyouts and later stage venture.
Business Model: B2B
Revenue: $6.7M
Employees: 11-50
Address: 222 Third Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture &a; growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Contact Phone:
+18579990339
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2020 | Lumeon | Series D | 0 |
8/2011 | ProFibrix | Series B | 10.6M |
1/2012 | Moximed | Venture Round | 1.8M |
9/2013 | Acacia Pharma | Series B | 23.5M |
3/2023 | FIRE1 | Venture Round | 0 |
1/2001 | Galapagos | Venture Round | - |
6/2006 | Agendia | Series C | - |
5/2012 | Prosonix | Series B | 0 |
6/2020 | Big Health | Series B | 39M |
12/2020 | Noema Pharma | Series A | 60M |
8/2009 | ProFibrix | Series B | 11.4M |
1/2022 | Big Health | Series C | 0 |
2/2022 | Nalu Medical | Venture Round | 0 |
1/2017 | LUMICKS | Series A | - |
9/2012 | BionX™ Medical Technologies | Series D | 0 |
1/2016 | Moximed | Series B | 12.6M |
2/2007 | Symphogen | Venture Round | 6.5M |
3/2018 | Inari Medical | Series C | 20.9M |
3/2016 | NIZO | Private Equity Round | - |
3/2021 | Amphista Therapeutics | Series B | 0 |
4/2021 | ADCendo | Series A | 61.8M |
7/2011 | Prosonix | Series B | 0 |
11/2013 | Sapiens Steering Brain Stimulation | Series C | 23M |
5/2018 | Lava Therapeutics | Series A | 18.7M |
5/2015 | Moximed | Series B | 33M |
3/2011 | Acacia Pharma | Series A | 10M |
1/2022 | ProVerum Medical | Series A | 0 |
7/2021 | Spire Health | Venture Round | 0 |
9/2020 | Lava Therapeutics | Series C | 83M |
5/2007 | Conatus Pharmaceuticals | Series A | 22M |
7/2015 | Vapotherm | Series C | 0 |
5/2017 | Vapotherm | Series D | 0 |
10/2002 | Pieris AG | Series A | 0 |
4/2016 | STAT-Dx | Series C | 0 |
8/2007 | Agendia | Series D | 34M |
9/2009 | Agendia | Series E | 23M |
1/2018 | FIRE1 | Series C | 49.6M |
12/2018 | Lumeon | Series C | 0 |
1/2019 | Ablative Solutions | Series D | 0 |
7/2020 | CVRx | Private Equity Round | 0 |
3/2017 | Breath Therapeutics | Series A | 45.9M |
3/2020 | AM Pharma | Venture Round | 25.4M |
8/2019 | CVRx | Series G | 93M |
3/2023 | GT Medical Technologies | Series C | 0 |
6/2014 | Definiens | Venture Round | 0 |
11/2011 | Fysius Rugexperts | Private Equity Round | - |
11/2010 | MTM Laboratories | Series C | 9.7M |
7/2017 | Axonics Modulation Technologies | Series C | 20.5M |
2/2019 | Calypso Biotech | Series A | 22.7M |
10/2010 | Stepping Stones Home &a; Care | Private Equity Round | - |
6/2015 | Zetacom | Private Equity Round | - |
9/2021 | Calypso Biotech | Series A | 0 |
8/2022 | Moximed | Series C | 0 |
4/2018 | Axonics Modulation Technologies | Series C | 40M |
10/2019 | Draupnir Bio | Venture Round | 33M |
7/2016 | Nyxoah | Series B | 19.9M |
8/2006 | Ablynx | Series C | 50M |
12/2007 | Ascendis Pharma | Series A | 25.7M |
12/2012 | Pharmaline | Private Equity Round | - |
1/2004 | Evotec | Venture Round | - |
7/2011 | VerzuimVitaal | Private Equity Round | - |
12/2015 | BionX™ Medical Technologies | Series E | 0 |
1/2006 | Symphogen | Series D | 0 |
8/2007 | FlowCardia | Series C | 0 |
6/2022 | Ablative Solutions | Series D | 0 |
6/2012 | Santaris Pharma | Venture Round | 12M |
7/2016 | Nightbalance | Series B | 0 |
3/2023 | Noema Pharma | Series B | 0 |
1/2023 | Volta Medical | Series B | 0 |
5/2019 | Vesper Medical | Venture Round | 0 |
3/2023 | Shoulder Innovations | Series D | 0 |
1/2002 | Innate Pharma | Series B | 17.8M |
12/2007 | Santaris Pharma | Series C | 30M |
4/2004 | Ablynx | Series B | 30M |
5/2012 | Agendia | Private Equity Round | 65M |
10/2012 | Definiens | Venture Round | 0 |
4/2014 | Vapotherm | Series B | 0 |
1/2021 | Volta Medical | Series A | 0 |
3/2017 | Moximed | Series C | 50M |
9/2018 | Vapotherm | Series D | 0 |
11/2011 | Inova Labs | Series B | 0 |
4/2006 | Chroma Therapeutics | Series C | 53M |
7/2008 | BG Medicine | Series D | 40M |
9/2014 | AM Pharma | Series E | 15.8M |
7/2020 | Withings | Series B | 0 |
4/2021 | LUMICKS | Series D | 0 |
6/2019 | SANIFIT | Series D | 0 |
6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
11/2003 | Roche Glycart | Series A | 13.6M |
6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
2/2022 | Splice Bio | Series A | 0 |
1/2015 | Novicare | Private Equity Round | - |
10/2014 | Levicept | Series A | 16.1M |
7/2019 | AM Pharma | Series F | 130.1M |
9/2002 | Ablynx | Series A | 4.9M |
6/2015 | Lumeon | Series B | 0 |
9/2015 | SANIFIT | Series C | 0 |
2/2011 | Conatus Pharmaceuticals | Series B | 0 |
7/2020 | Eargo | Series E | 0 |
10/2009 | MTM Laboratories | Series C | 57.1M |
4/2023 | ADCendo | Series A | 0 |
6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
4/2023 | ADCendo | Series A | 0 |
3/2023 | GT Medical Technologies | Series C | 0 |
3/2023 | FIRE1 | Venture Round | 0 |
3/2023 | Noema Pharma | Series B | 0 |
3/2023 | Shoulder Innovations | Series D | 0 |
1/2023 | Volta Medical | Series B | 0 |
8/2022 | Moximed | Series C | 0 |
6/2022 | Ablative Solutions | Series D | 0 |
2/2022 | Nalu Medical | Venture Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|